ReviewArthritis research & therapy2009
The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
Review in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 58 citations in OpenAlex.
- Very low calorie ketogenic diet and common rheumatic disorders: A case report.World journal of clinical cases · 2023Article
- Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Frontiers in immunology · 2022Review
- Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms.Rheumatology (Oxford, England) · 2019Article
- Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis.Experimental and therapeutic medicine · 2019Article
- Increased Binding of Specificity Protein 1 to theFrontiers in immunology · 2018Article
- Regulation of matrix metalloproteinase-1 and alpha-smooth muscle actin expression by interleukin-1 alpha and tumour necrosis factor alpha in hepatic stellate cells.Cytotechnology · 2017Article
- Deconstructing innate immune signaling in myelodysplastic syndromes.Experimental hematology · 2015Review
- Biomarkers in systemic lupus erythematosus: challenges and prospects for the future.Therapeutic advances in musculoskeletal disease · 2013Article
- The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- The dysregulation of cytokine networks in systemic lupus erythematosus.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2011Review
- Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population.Clinical and experimental medicine · 2011Article
- IL-17 contributes to angiogenesis in rheumatoid arthritis.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- The IL-1 family: regulators of immunity.Nature reviews. Immunology · 2010Review
- Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management?Open access rheumatology : research and reviews · 2010Review
- The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.Journal of biomedicine & biotechnology · 2010Article
- [Interleukin-1 cytokines, inflammasomes, NOD-signalosomes and autoinflammation].Zeitschrift fur Rheumatologie · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better understanding of cytokine biology over the last two decades has allowed the successful development of cytokine inhibitors against tumour necrosis factor and interleukin (IL)-1 and IL-6. The introduction of these therapies should be considered a breakthrough in the management of several rheumatic diseases. However, many patients will exhibit no or only partial response to these therapies, thus emphasising the importance of exploring other therapeutic strategies. In this article, we review the most recent information on novel cytokines that are often members of previously described cytokine families such as the IL-1 superfamily (IL-18 and IL-33), the IL-12 superfamily (IL-27 and IL-35), the IL-2 superfamily (IL-15 and IL-21), and IL-17. Several data derived from experimental models and clinical samples indicate that some of these cytokines contribute to the pathophysiology of arthritis and other inflammatory diseases. Targeting of some of these cytokines has already been tested in clinical trials with interesting results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.